Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5147]

Adjuvant docetaxel fails after radical prostatectomy for high risk prostate...

Dr Goran Ahlgren - Lund University, Malmö, Sweden

Adjuvant docetaxel fails after radical prostatectomy for high risk prostate cancer ( Dr Goran Ahlgren - Lund University, Malmö, Sweden )

Sequencing analysis with circulating DNA

Dr Oliver Zill - Guardant Health Inc, Brentwood City, USA

Sequencing analysis with circulating DNA ( Dr Oliver Zill - Guardant Health Inc, Brentwood City, USA )

Targetting PD-L1 with avelumab in metastatic Merkel cell carcinoma

Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, USA

Targetting PD-L1 with avelumab in metastatic Merkel cell carcinoma ( Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, USA )

Ten years of letrozole improves survival and quality of life in early-diagnosed...

Dr Julie Lemieux - Hôpital du Saint-Sacrement, Québec, Canada

Ten years of letrozole improves survival and quality of life in early-diagnosed breast cancer. ( Dr Julie Lemieux - Hôpital du Saint-Sacrement, Québec, Canada )

Daratumumab slows progression in refractory multiple myeloma

Prof Palumbo - University of Turin, Turin, Italy

$Daratumumab slows progression in refractory multiple myeloma ( Prof Palumbo - University of Turin, Turin, Italy )$

Developments in haematological malignancies

Dr Stephen Nimer - University of Miami, Miami, USA

Developments in haematological malignancies ( Dr Stephen Nimer - University of Miami, Miami, USA )

Recent developments in targeted therapies

Dr Stephen Nimer - University of Miami, Miami, USA

Recent developments in targeted therapies ( Dr Stephen Nimer - University of Miami, Miami, USA )

First results of a prospective bendamustine/rituximab trial in patients with MCL

Dr Mathias Rummel - University of Giessen, Giessen, Germany

First results of a prospective bendamustine/rituximab trial in patients with MCL ( Dr Mathias Rummel - University of Giessen, Giessen, Germany )

MyPathway guidance of targeted therapy based on molecular profiles

Dr John Hainsworth - Sarah Cannon Research Institute, Nashville, USA

MyPathway guidance of targeted therapy based on molecular profiles ( Dr John Hainsworth - Sarah Cannon Research Institute, Nashville, USA )

Testing the safety and efficacy of the PD-L1 antibody durvalumab

Dr Christophe Massard - Institut Gustave Roussy, Paris, France

Testing the safety and efficacy of the PD-L1 antibody durvalumab ( Dr Christophe Massard - Institut Gustave Roussy, Paris, France )

Upfront autologous stem cell transplantation for newly diagnosed multiple...

Prof Michele Cavo - Seràgnoli Institute of Hematology, Bologna, Italy

Upfront autologous stem cell transplantation for newly diagnosed multiple myeloma ( Prof Michele Cavo - Seràgnoli Institute of Hematology, Bologna, Italy )

ASCO 2016: What is the optimal chemotherapy dosing regimen for prostate cancer?

Prof Charles Ryan and Prof Nick James

ASCO 2016: What is the optimal chemotherapy dosing regimen for prostate cancer? ( Prof Charles Ryan and Prof Nick James )

More from ecancer